News
Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...
VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.
Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.
18h
MarketBeat on MSNWhy Hims & Hers Is a Buy Below $35 After Its 16% PullbackThere is always a challenging moment in every investor’s favorite stock and portfolio, especially when said businesses are ...
Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results